Plus Therapeutics Inc (PSTV)

02:36 AM

Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN

02:36 AM

May 03, 2026

PSTV stock on track for best week since September — here’s what is driving the rally - MSN

May 03, 2026

May 01, 2026

PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill

May 01, 2026

Apr 30, 2026

Plus Therapeutics Analyst Ratings and Price Targets | NASDAQ:PSTV - Benzinga

Apr 30, 2026

Apr 30, 2026

Plus Therapeutics (PSTV) price target decreased by 72.34% to 38.76 - MSN

Apr 30, 2026

Apr 29, 2026

Plus Therapeutics, Inc. Income Statement – GETTEX:XMP1 - TradingView

Apr 29, 2026

Apr 28, 2026

Plus Therapeutics regains compliance with Nasdaq - MSN

Apr 28, 2026

Apr 28, 2026

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Yahoo Finance

Apr 28, 2026

Apr 27, 2026

Plus Therapeutics announces 1-for-25 reverse stock split - MSN

Apr 27, 2026

Apr 26, 2026

Why is Plus Therapeutics stock gaining Friday? - MSN

Apr 26, 2026

Apr 25, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 25, 2026

Apr 24, 2026

Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga

Apr 24, 2026

Apr 24, 2026

PSTV Should I Buy - Intellectia AI

Apr 24, 2026

Apr 23, 2026

Plus Therapeutics Initiates Manufacturing Activities, Tech Transfer With SpectronRx - Contract Pharma

Apr 23, 2026

Apr 23, 2026

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - The Manila Times

Apr 23, 2026

Apr 23, 2026

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ - ChartMill

Apr 23, 2026

Apr 23, 2026

PSTV (PLUS THERAPEUTICS Inc.) reports wider than expected Q4 2025 loss but gains 7.39 percent on optimistic investor outlook.Earnings Surprise - Xã Thanh Hà

Apr 23, 2026

Apr 23, 2026

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN

Apr 23, 2026

Apr 22, 2026

Plus Therapeutics (PSTV) CDO receives new options and RSU grants - Stock Titan

Apr 22, 2026

Apr 22, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 22, 2026

Apr 22, 2026

Plus Therapeutics Regains Nasdaq Listing Compliance After Reverse Split - The Globe and Mail

Apr 22, 2026

Apr 21, 2026

PSTV Financials: Income Statement, Balance Sheet & Cash Flow | Plus Therapeutics Inc - Stock Titan

Apr 21, 2026

Apr 21, 2026

Plus Therapeutics (PSTV) CDO reports no common stock ownership - Stock Titan

Apr 21, 2026

Apr 21, 2026

Plus Therapeutics | 8-K: Current report - Moomoo

Apr 21, 2026

Apr 21, 2026

Plus Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement for CNS Cancer Therapies 1 - Minichart

Apr 21, 2026

Apr 21, 2026

Plus Therapeutics (PSTV) Meets Nasdaq Bid Price Requirement - GuruFocus

Apr 21, 2026

Apr 21, 2026

Plus Therapeutics regains Nasdaq compliance after one-for-25 reverse split - TradingView

Apr 21, 2026